Sulamid

Quick links to important sections

Sulamid

Method of action: Antipsychotic, Psycholeptics

Treatment option: Delirium, Hallucinations

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulamid

Quick Facts

Property Description
Active ingredient Amisulpride
Forms Tablets (Oral), Solution (Intravenous)
Pharmacological class Atypical Antipsychotic, Dopamine D2/D3 Antagonist
General purpose Central Nervous System stabilization, Anti-emetic
Origin Synthetic substituted benzamide derivative

What Type of Medicine is Sulamid?

Sulamid is the trade designation for the pharmaceutical product containing the active substance Amisulpride, a synthetic compound classified chemically as a substituted benzamide derivative. Amisulpride is globally recognized as an atypical antipsychotic, often referred to as a second-generation antipsychotic. Its highly selective action on specific neural pathways gives it a distinctive profile compared to older treatments. Amisulpride operates as a selective Dopamine D2 and D3 receptor antagonist, meaning it primarily influences the activity of the chemical messenger dopamine in the brain's limbic system. Amisulpride is an atypical antipsychotic drug used for those with schizophrenia.

Composition, Forms, and General Purpose

Sulamid is exclusively a single-component product, with Amisulpride as the sole active ingredient, delivered via either tablets for oral administration or a sterile aqueous solution for intravenous administration. The product's overall therapeutic role is two-pronged: primarily, it is clinically recognized for its ability to stabilize central nervous system function, often utilized in scenarios involving significant disruptions in mental processes. Secondarily, it is used as an anti-emetic. Intravenous Amisulpride is used in the prevention and treatment of post-operative nausea and vomiting. The medicine offers a function in controlling nausea and vomiting, especially after surgical procedures.

What side effects are possible with Sulamid?

Possible Side Effects and Safety Information

The safety profile of Sulamid, which represents products containing active substances like mesalamine or amisulpride, is defined by common non-serious reactions as well as rare, serious organ-specific risks.

Adverse Reactions Summary

Classification Examples of Documented Reactions
Most Common (ge 2%) Headache, nausea, nasopharyngitis, abdominal pain, and worsening of the underlying condition (for mesalamine-containing products); increased blood prolactin concentrations, chills (for amisulpride-containing products).
Serious / Clinically Significant Renal impairment (including renal failure), hepatic failure, Mesalamine-induced Acute Intolerance Syndrome, hypersensitivity reactions (including myocarditis and pericarditis), Severe Cutaneous Adverse Reactions.

Safety Considerations and Restrictions

Renal and Hepatic Monitoring: Regulatory documents require the assessment of renal function prior to and periodically during mesalamine therapy, particularly in patients with pre-existing renal impairment or those taking nephrotoxic drugs. Caution is also advised in patients with known liver impairment.

Cardiovascular Risk (Amisulpride): Amisulpride causes dose- and concentration-dependent QT prolongation. Its use is avoided in patients with congenital long QT syndrome. Electrocardiogram (ECG) monitoring is recommended for patients with pre-existing cardiac disorders or electrolyte abnormalities.

Specific Populations: Geriatric patients taking mesalamine may have an increased risk of blood dyscrasias, necessitating monitoring of complete blood cell counts and platelet counts.

Acute Intolerance: Patients should be monitored for the Mesalamine-induced Acute Intolerance Syndrome, as its symptoms may mimic an exacerbation of the underlying disease and require immediate discontinuation if suspected.

Overdose and Emergency Response

Sulamid Overdose and When to Seek Help

Sulamid is the brand name for sulfacetamide, an antibiotic belonging to the sulfonamide class. Due to its topical and ophthalmic formulations, systemic overdose from typical therapeutic use is unlikely. However, in cases of extensive application to large, abraded, or compromised skin areas, or accidental ingestion, systemic absorption leading to toxicity is possible.

Overdose symptoms may include signs associated with systemic sulfonamide absorption, which can affect multiple organ systems. These effects often manifest as adverse reactions to the drug class, potentially becoming severe with excessive exposure. Management of an overdose is supportive, focusing on symptomatic treatment and monitoring of vital functions, as there is no specific antidote.

System Affected Potential Symptoms
Gastrointestinal Nausea, vomiting, abdominal cramps
Hematologic Fever, sore throat, pale skin, easy bruising (signs of blood dyscrasias like agranulocytosis or hemolytic anemia)
Renal Reduced urination, blood in urine (signs of kidney toxicity)

When to Seek Immediate Medical Help

Call for emergency medical assistance immediately if you suspect an overdose or observe any of the following severe symptoms in yourself or another person after Sulamid exposure:

  • Signs of a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face, lips, tongue, or throat).
  • Signs of a serious skin reaction (e.g., blistering, peeling, red or purple rash).
  • Severe, persistent vomiting or abdominal pain.
  • Confusion, drowsiness, or loss of consciousness.

In non-emergency situations where a larger-than-prescribed amount was used or ingested, contact a poison control center for guidance.

Therapeutic Uses of Sulamid

Sulamid is commonly used across conditions involving episodic or fluctuating manifestations where supportive symptomatic management is appropriate in adults. The primary therapeutic application is the management of schizophrenia, and it is relevant for easing the intensity of both positive symptoms (like delusions and hallucinations) and negative symptoms (such as emotional withdrawal and blunted affect). The medication is also applied in the surgical setting, where it is used to prevent and address postoperative nausea and vomiting (PONV).

In these clinical scenarios, the medication provides support that helps ease the overall burden of symptoms that interfere with daily functioning. The medication may assist with maintaining functional stability during symptomatic phases.

“This medication is applied in situations involving certain distressing symptoms across two distinct therapeutic domains: psychiatric stabilization and anti-emetic support.”


Quick Fact: Symptomatic Management

Domain Benefit Symptom Types Managed
Psychiatric Care Supports functional stability Delusions, hallucinations, emotional withdrawal
Surgical Recovery Contributes to improved comfort Nausea, vomiting, post-anesthesia distress

Eligibility and Restrictions for Use

The eligibility for Sulamid (Amisulpride) is strictly defined by regulatory authorities and is generally limited to adults (18 years and older). Use is contraindicated (absolutely prohibited) for several patient populations.

Contraindicated Populations (Must Not Use) Special Populations Requiring Restriction
Children under 15 years of age. Adolescents (15–18 years) use is not recommended due to limited data.
Patients with Hypersensitivity to the drug. Older adults require particular caution due to the risk of hypotension or sedation.
Patients with Prolactin-dependent tumors (e.g., breast cancer). Use in pregnancy is not recommended; use during lactation is contraindicated.
Patients with Pheochromocytoma. Patients with renal impairment (CrCL 10 to 60 mL/min) require an official dose reduction.
Severe renal impairment (CrCL < 10 mL/min). Hepatic insufficiency does not require a dose adjustment.

Comorbidity-dependent eligibility rules also mandate caution for patients with a history of seizures or Parkinson's disease, as the medicine may potentially lower the seizure threshold or worsen the disease, respectively. The official profile strictly defines these exclusions and conditions based on organ function, age, and existing physiological states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Sulamid (Amisulpride) as specified in government regulatory labeling.

Contraindicated Combinations

Co-administration is strictly prohibited with substances formally documented as increasing the risk of severe outcomes. These include non-antiparkinsonian dopamine agonists (such as cabergoline and quinagolide) and medicines classified as likely to induce Torsades de Pointes, specifically Class Ia and III antiarrhythmics. The combination with Levodopa is also contraindicated due to a documented reciprocal antagonism of effects. Other prohibited substances include citalopram, escitalopram, domperidone, hydroxyzine, and piperaquine.


Pharmacodynamic and Exposure Interactions

Co-use with sedative drugs (e.g., neuroleptics, benzodiazepines, hypnotics) may cause officially documented additive depressant effects on the central nervous system. Caution is required with antihypertensive and hypotensive medications due to potential potentiation of effect. Amisulpride is weakly metabolized; however, co-administration with Clozapine may lead to a documented increase in plasma levels. The drug may be taken without regard to meals, but consumption of alcohol is not recommended as it may enhance central effects.


Population-Specific Notes

Due to the drug's primary renal elimination, patients with Renal Insufficiency have an officially noted risk of increased exposure. The risk of serious ventricular arrhythmias is formally noted as being worsened in patients with pre-existing conditions such as Bradycardia or Electrolyte Abnormalities.

Mechanism of Action

Sulamid is classified as a selective A1 kinase inhibitor. Its primary function is the modulation of intracellular signaling pathways involved in bone resorption.

The drug acts by binding directly to the ATP-binding pocket on the A1 kinase active site. This A1 kinase is a component in the signaling cascade downstream of receptor activator of nuclear factor kappa B ligand ( RANKL) activation. The resulting competitive inhibition prevents the phosphorylation of NF-kB subunits.

The consequential reduction in NF-kB activation limits its translocation to the nucleus. This action downregulates the transcription of several genes critical for osteoclast maturation, activity, and survival, including those encoding cathepsin K and matrix metalloproteinases ( MMP9).

The physiological consequence of A1 kinase inhibition is the attenuation of osteoclast differentiation and a decrease in the overall rate of bone resorption.

Dosage and Administration Information

How to Use Sulamid

Sulamid (amisulpride) is administered through specific routes and regimens, reflecting its distinct uses in psychiatric and surgical care. The medication is available as oral tablets and oral solution for long-term use, and as an intravenous (IV) solution for single-use, acute applications.


Administration Routes and Standard Dosing

Indication Context Route & Frequency Standard Adult Dose Range Special Instruction
Psychiatric Care (Schizophrenia) Oral: Once daily for doses le 300 mg/day. Divided doses (BID) for doses > 300 mg/day. 50 mg/day to 1200 mg/day (maximum) Doses should preferably be taken before meals.
Surgical Care (PONV) Intravenous: Single administration. 5 mg (prevention) or 10 mg (treatment) IV administration is given as a 1 to 2 minute infusion.

Procedural and Population Constraints

Oral administration is typically continued long-term for maintenance, while the IV form is strictly a single, acute-use product. Tablets can be divided into equal halves when necessary to achieve the prescribed dose.

Dose adjustments are based on renal function. For moderate renal impairment (creatinine clearance 30-60 mL/min), the oral dose must be halved. For severe impairment (CrCl 10-30 mL/min), the dose is reduced to one-third of the usual amount. No dosage reduction is required for patients with hepatic impairment. Use is contraindicated in children under 15 years old.

Recent Clinical Evidence

The clinical evaluation of Sulamid (Amisulpride) is grounded in Randomized Controlled Trials (RCTs) and meta-analyses across its main therapeutic areas.

For the management of schizophrenia, research primarily focused on adults experiencing acute periods of heightened symptom activity or those with predominantly negative symptoms. Studies examined changes in standardized scores for both positive symptoms (e.g., delusions) and negative symptoms (e.g., emotional withdrawal) over defined short-term (four to eight weeks) and intermediate intervals. Findings describe patterns observed in these studies regarding measured changes in symptom severity. However, long-term functional outcomes are not fully established beyond one year, and comparative evidence remains limited against all other available atypical antipsychotics.

In the surgical setting, Sulamid was studied for Postoperative Nausea and Vomiting (PONV). This evidence is based on large, placebo-controlled trials evaluating its use for both prevention (prophylaxis) and treatment (rescue) in adults undergoing general anesthesia. Researchers monitored outcomes related to physical discomfort, tracking the rate of Complete Response (no vomiting or retching, and no required rescue medication) within the immediate 24-hour post-operative period. Research for this indication is largely restricted to the acute, single intravenous dose setting. Data for specific subgroups, such as older adults or the oral formulation in this context, remain insufficient.

Key Studies & References Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis

Frequently Asked Questions (FAQ)

Common questions about Sulamid (FAQ)

Q: Does Sulamid require a prescription?

Yes, official classification states that Sulamid (Amisulpride) is a prescription-only medicine. It is not available for purchase without authorization from a healthcare professional.

Q: Why is Sulamid only available by prescription?

Sulamid is designated as a prescription-only medicine due to its classification as a powerful antipsychotic medicine. This class of drug requires monitoring by a healthcare professional because of its potential for serious side effects, such as QT prolongation (a heart rhythm issue), and complex drug interactions.

Q: What is the mechanism of action of Sulamid in simple, patient-friendly terms?

Sulamid (Amisulpride) works by selectively blocking the activity of specific chemical messengers in the brain called Dopamine D2 and D3 receptors. This is known as the drug's mechanism of action. According to official documents, this targeted action helps to stabilize chemical imbalances associated with its intended uses.

Q: How long until I should expect to notice the effects of Sulamid?

Studies and official prescribing guides indicate that some improvements in acute symptoms may begin to be noticed within about one week of beginning treatment. However, achieving the full therapeutic effect and stabilization of symptoms usually requires patience. The effectiveness is typically assessed after several weeks, for example, between four to six weeks of consistent use.

Q: Does Sulamid need to be taken consistently at the same time each day to work?

Official instructions indicate that Sulamid is prescribed to be taken as a once-daily dose or divided into two doses per day, depending on the prescribed amount. Following this required frequency is important to maintain stable concentrations of the medicine in the body over time and supports consistent results.

Q: How long does Sulamid stay in your system after you stop taking it?

Official pharmacokinetic data describes how the body processes the medicine. The elimination half-life of Sulamid (Amisulpride) is approximately 12 hours after an oral dose. This means that it takes about 12 hours for the concentration of the medicine in the bloodstream to be reduced by half.

Q: What is a 'precautions' warning in the context of Sulamid use?

In regulatory documentation, precautions refer to special warnings for specific situations or patient groups. These are conditions, like having a history of seizures or being an elderly patient, where the medicine should be used with particular caution or require close medical monitoring. This section guides healthcare providers on minimizing risk.

Q: Are there any known long-term safety concerns associated with Sulamid use?

Official warnings indicate that Sulamid use may be associated with potential long-term effects. These include a rare risk of uncontrolled movements, known as tardive dyskinesia, which usually occurs with prolonged use. Official information also notes the importance of monitoring for metabolic changes, such as weight gain and elevated blood sugar, during long-term treatment.

Q: Do side effects from Sulamid usually go away after the body adjusts?

The reversibility of side effects varies based on the specific effect. Some dose-related side effects, such as uncontrolled movements (Extrapyramidal Symptoms), are described as generally mild and often improve with adjustments or co-treatment. An increase in prolactin levels is also noted as being reversible after the drug is stopped.

Q: Can Sulamid cause weight changes, either gain or loss?

Official regulatory documents list weight gain as a common side effect observed in patients using Sulamid. Information on the product does not commonly list weight loss as an expected change.

Q: Can Sulamid affect the way birth control or hormone therapy works?

Sulamid commonly causes an increase in plasma prolactin levels, which is a known hormonal change. This increase may lead to disturbances in women's menstrual cycles, such as missed or irregular periods (amenorrhoea), and other related symptoms. This indicates a functional effect on hormone regulation.

Q: Does Sulamid affect sleep patterns or cause insomnia?

Official documents list that Sulamid can affect sleep patterns. Both insomnia (difficulty sleeping) and somnolence (drowsiness) are listed as common side effects.

Q: Is there a recommendation about driving or operating heavy machinery while on Sulamid?

The official product information includes a specific section regarding the ability to drive. Because Sulamid carries a risk of somnolence (drowsiness), the information advises that the ability to safely drive vehicles or operate heavy machinery may be reduced, even when the medicine is used as prescribed.

Q: Can Sulamid affect my blood sugar levels or diabetes management?

Regulatory information lists hyperglycaemia (elevated blood sugar) as an uncommon adverse effect and advises caution for patients with a known history of diabetes.

Q: Where can I find the official prescribing information for Sulamid?

The complete and official prescribing details for Sulamid are published by national regulatory authorities. In the United States, this information is available through the FDA in databases like DailyMed. For European users, the data is found in the European Medicines Agency's (EMA) public documents, such as the Summary of Product Characteristics (SmPC).

Q: How recently was the drug Sulamid first introduced?

The active substance in Sulamid (Amisulpride) was first synthesized in the mid-1970s. The medicine was initially made available in Europe in the early 1990s following its regulatory authorization.

How should Sulamid be stored and disposed of?

Storage and Disposal Requirements

Official storage and disposal rules for Amisulpride are based on the dosage form to ensure product integrity. Amisulpride tablets should be stored in their original package and at a temperature not exceeding 25°C (77°F), with no other special precautions required.

Dosage Form Temperature & Light Constraint
Oral Tablets Store below 25 C / In original package
IV Solution Protect from light / No refrigeration is needed

The intravenous solution must be stored in its protective carton and protected from light. Once removed from the carton, it must be administered within 12 hours to maintain stability. All forms must be kept out of the reach of children. Unused or expired medicine and containers must be disposed of according to local, regional, and national regulations, and must not be allowed to enter sewers or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulamid found in:

A-Z Index: